Studies whether flozin drugs help prevent kidney injury from contrast dye
Observes flozin use and kidney injury after heart procedures with contrast dye in adults.
Plain-language title generated from the registry record
Registry title: Use of Flozins (Empagliflozin/Dapagliflozin) for Prevention of AKI
Key facts
- Where
- Bydgoszcz, PolandSee the site
Where in Poland
- Collegium Medicum w BydgoszczyBydgoszcz, PolandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Collegium Medicum w Bydgoszczy
- Trial code
- NCT07231939
- Record updated
- 17 November 2025
- Original description
All consecutive patients hospitalized from 01.01.2020 to 30.09.2025 who underwent coronary angiography or PCI will be eligible for inclusion.Read full original descriptionShow less
FLOzins for pREveNtion of Contrast-inducEd Acute Kidney Injury (FLORENCE) Study
All consecutive patients hospitalized from 01.01.2020 to 30.09.2025 who underwent coronary angiography or PCI will be eligible for inclusion.
The final analysis will be limited to individuals in whom the volume of ICM administered during the index procedure was between 50 and 500 mL and for whom both pre- and post-procedure serum creatinine measurements were available.
The primary objective of the study is the effect of short-term and long-term SGLT2i therapy on the occurrence of CI-AKI in patients undergoing diagnostic or therapeutic procedures with ICM.
Inclusion: all consecutive patients who underwent PCI or coronary angiography during the study period for whom the variables required for the analysis are available.
Exclusion: unavailability of variables required for the analysis, volume; contrast agent volume <50 mL or >500 mL.